Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
ADB-CHMINACA
open-in-new
<p>ADB-CHMINACA (also known as ADMB-CHMINACA and MAB-CHMINACA) is an <a href="/facts/Indazole/cxuExFaI">indazole</a>-based <a href="/facts/Synthetic_cannabinoid/gezRArqa">synthetic cannabinoid</a>. It is a potent <a href="/facts/Agonist/nz8U5NNp">agonist</a> of the <a href="/facts/CB1_receptor/7b2tfePV">CB1 receptor</a> with a binding affinity of <i>K</i>i = 0.289 nM and was originally developed by <a href="/facts/Pfizer/1ADDanWs">Pfizer</a> in 2009 as an <a href="/facts/Analgesic/xLj4XBcq">analgesic</a> medication. It was identified in cannabinoid blends in Japan in early 2015. </p>